Table 2.
Vaccine distribution in people with multiple sclerosis in Germany and the United Kingdom.
| Vaccine | Vaccine | Tozinameran | Elasomeran | AZD1222 | Ad26.COV2.S |
|---|---|---|---|---|---|
| Preparation | Comirnaty® | Spikevax® | Vaxzevria® | COVID-19 Vaccine Janssen | |
| Company | BioNTech/ Pfizer | Moderna | AstraZeneca | Janssen/ Johnson&Johnson | |
| Vaccination frequency in MS N (%)I | |||||
| GER | |||||
| Solely (NI=1682) | 1424 (84·7) | 177 (10·5) | 64 (3·8) | 17 (1·0) | |
| Heterologous after X1 (NI=165) | 3 (1·8) | 4 (2·4) | 158 (95·8) | 0 (0·0) | |
| UK | |||||
| Solely (NI=675) | 256 (37·9) | 0 (0·0) | 419 (62·1) | 0 (0·0) | |
| Heterologous after X1 (NI=8) | 2 (25·0) | 1 (12·5) | 5 (62·5) | 0 (0·0) | |
| Applied vaccine doses in the general population (GER), N (%)II× | Total: 74,896,395 (75·4) |
Total: 9,167,210 (9·2) |
Total: 12,631,735 (12·7) |
Total: 2,690,046 (2·7) |
|
| X1 (NII=53,276,005) | 37,004,574 (69·5) | 4,359,449 (8·2) | 9,221,989 (17·3) | 2,689,993 (5·0) | |
| X2 (NII=46,104,401) | 37,887,668 (82·2) | 4,807,022 (10·4) | 3,409,711 (7·4) | 0 (0·0) | |
| X3 (NII=4980) | 4153 (83·4) | 739 (14·8) | 35 (0·7) | 53 (1·1) | |
| Applied vaccine doses in the general population (UK), N (%)IIa | Total: 25,613,328 (40·9) |
Total: 442,837 (0·7) |
Total: 36,602,474 (58·4) |
Total: 0 (0·0) |
|
| X1 (NII=38,614,683) | 15,424,349 (39·9) | 405,814 (1·1) | 22,784,520 (59·0) | 0 (0·0) | |
| X2 (NII=24,043,956) | 10,284,910 (42·8) | 1,645 (<0·01) | 13,757,400 (57·2) | 0 (0·0) | |
| Approval date | |||||
| EMA (GER) | 21/12/2020 | 06/01/2021 | 29/01/2021 | 11/03/2021 | |
| MHRA (UK) | 21/12/2020 | 08/01/2021 | 30/12/2020 | 28/05/2021 | |
EMA – European Medicines Agency.
GER – Germany.
MHRA (UK) – Medicines & Healthcare products Regulatory Agency (United Kingdom).
MS – multiple sclerosis.
N (%)I – number of patients (proportion of patients).
N (%)II – number of applied vaccine doses (proportion of applied doses).
SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2.
UK – United Kingdom.
X1 – first SARS-CoV-2 vaccination.
X2 – second SARS-CoV-2 vaccination.
X3 – booster vaccination.
× – according to reports of the Robert Koch Institute(Germany) and referred to a total of 99,385,386 applied vaccine doses in Germany (status 19/08/2021).18
– according to reports of the UK COVID-19 dashboard and referred to a total of 62,658,639 applied vaccine doses in the UK, extrapolated from Welsh trends (status 26/05/2021).19